208 related articles for article (PubMed ID: 31612051)
21. Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway.
Liao XZ; Gao Y; Zhao HW; Zhou M; Chen DL; Tao LT; Guo W; Sun LL; Gu CY; Chen HR; Xiao ZW; Zhang JX; He MF; Lin LZ
Front Cell Dev Biol; 2020; 8():609285. PubMed ID: 33520990
[TBL] [Abstract][Full Text] [Related]
22. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
23. The CK2 inhibitor CX4945 reverses cisplatin resistance in the A549/DDP human lung adenocarcinoma cell line.
Jin C; Song P; Pang J
Oncol Lett; 2019 Oct; 18(4):3845-3856. PubMed ID: 31579410
[TBL] [Abstract][Full Text] [Related]
24. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
25. Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer.
Ji J; Zhen W; Si Y; Ma W; Zheng L; Li C; Zhang Y; Qin S; Zhang T; Liu P; Zheng X; Liu Y
Cancer Biomark; 2018 Feb; 21(2):307-316. PubMed ID: 29103022
[TBL] [Abstract][Full Text] [Related]
26. Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway.
Tang XL; Yan L; Zhu L; Jiao DM; Chen J; Chen QY
J Pharmacol Sci; 2017 Sep; 135(1):1-7. PubMed ID: 28939129
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: an in vitro study.
Zhang X; Xu B; Sun C; Wang L; Miao X
Int J Clin Exp Med; 2015; 8(9):16941-7. PubMed ID: 26629248
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.
Han ML; Zhao YF; Tan CH; Xiong YJ; Wang WJ; Wu F; Fei Y; Wang L; Liang ZQ
Acta Pharmacol Sin; 2016 Dec; 37(12):1606-1622. PubMed ID: 27840408
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
30. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
31. Down-Regulating the Expression of miRNA-21 Inhibits the Glucose Metabolism of A549/DDP Cells and Promotes Cell Death Through the PI3K/AKT/mTOR/HIF-1α Pathway.
Sun Y; Liu W; Zhao Q; Zhang R; Wang J; Pan P; Shang H; Liu C; Wang C
Front Oncol; 2021; 11():653596. PubMed ID: 34046349
[TBL] [Abstract][Full Text] [Related]
32. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of close homolog of L1 enhances the chemosensitivity of lung cancer cells via inhibition of the Akt pathway.
Cai X; Hu B; Liu S; Liu M; Huang Y; Lei P; Zhang Z; He Z; Zhang L; Huang R
Oncol Lett; 2020 Oct; 20(4):111. PubMed ID: 32863924
[TBL] [Abstract][Full Text] [Related]
34. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
35. Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer.
Teng JF; Qin DL; Mei QB; Qiu WQ; Pan R; Xiong R; Zhao Y; Law BY; Wong VK; Tang Y; Yu CL; Zhang F; Wu JM; Wu AG
Pharmacol Res; 2019 Sep; 147():104396. PubMed ID: 31404628
[TBL] [Abstract][Full Text] [Related]
36. Tumstatin 185-191 increases the sensitivity of non-small cell lung carcinoma cells to cisplatin by blocking proliferation, promoting apoptosis and inhibiting Akt activation.
Wang W; Chen P; Tang M; Li J; Pei Y; Cai S; Zhou X; Chen S
Am J Transl Res; 2015; 7(8):1332-44. PubMed ID: 26396665
[TBL] [Abstract][Full Text] [Related]
37. Polyphyllin VII induces autophagy-dependent ferroptosis in human gastric cancer through targeting T-lymphokine-activated killer cell-originated protein kinase.
Xiang Y; Wan F; Ren Y; Yang D; Xiang K; Zhu B; Ruan X; Li S; Zhang L; Liu X; Si Y; Liu Y
Phytother Res; 2023 Dec; 37(12):5803-5820. PubMed ID: 37632389
[TBL] [Abstract][Full Text] [Related]
38. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
Wei L; Qu W; Sun J; Wang X; Lv L; Xie L; Song X
Cancer Gene Ther; 2014 May; 21(5):194-9. PubMed ID: 24874844
[TBL] [Abstract][Full Text] [Related]
40. AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway.
Liu Y; Hu Q; Wang X
Oncol Lett; 2020 Jan; 19(1):1024-1030. PubMed ID: 31897216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
